Chronic Myeloid Leukemia in Chronic Phase
Oncology
Prevalence
5.0 / 100K
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| Asciminib | Novartis AG (NVS) |
Phase 4(1)
| Drug | Company |
|---|---|
| asciminib | Novartis AG (NVS) |
Frequently asked questions
How many drugs are in development for Chronic Myeloid Leukemia in Chronic Phase?
BioSniper tracks 2 drugs in development for Chronic Myeloid Leukemia in Chronic Phase across 1 company.
How many clinical trials target Chronic Myeloid Leukemia in Chronic Phase?
There are 1 clinical trial targeting Chronic Myeloid Leukemia in Chronic Phase tracked by BioSniper.
What is the prevalence of Chronic Myeloid Leukemia in Chronic Phase?
The estimated prevalence of Chronic Myeloid Leukemia in Chronic Phase is approximately 5.0 per 100,000 population.
Deep-dive into Chronic Myeloid Leukemia in Chronic Phase
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis